
Sign up to save your podcasts
Or


Are you asking about sleep, activity levels, and mood? Why you should be and what to do next.
Credit available for this activity expires: 12/31/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/achieving-brain-health-epilepsy-what-can-clinicians-do-2025a1000y6t?ecd=bdc_podcast_libsyn_mscpedu
Discover the patients who need timely treatment for metabolic dysfunction–associated steatohepatitis (MASH). How will you find them? And then what will you do?
Credit available for this activity expires: [12/30/26] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patient-case-challenge-how-would-you-manage-this-patient-2025a1000zqo?ecd=bdc_podcast_libsyn_mscpedu
Alarming in immunoglobulin A nephropathy (IgAN): over 40% present late. Explore latest advancements in management of the most common cause of primary glomerulonephritis worldwide.
Credit available for this activity expires: 12/23/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-challenges-igan-management-clinical-implications-2025a1000w9b?ecd=bdc_podcast_libsyn_mscpedu
How well are you managing patients on EGFR inhibitor therapies in your clinical practice?
Credit available for this activity expires: 12/18/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/person-centered-care-egfr-mutated-advanced-nsclc-optimizing-2025a1000xxa?ecd=bdc_podcast_libsyn_mscpedu
Learn from the experts about selecting the right BTK inhibitor therapy for patients with chronic lymphocytic leukaemia (CLL) in UK clinical practice.
Credit available for this activity expires: 12/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/charting-course-cll-clinicians-compass-btk-inhibitor-therapy-2025a1000yei?ecd=bdc_podcast_libsyn_mscpedu
Did you know that, while well established in the metastatic setting, second-generation antibody-drug conjugates are now moving into the early setting?
Credit available for this activity expires: 12/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-adcs-shaping-future-early-breast-cancer-care-latest-2025a1000yca?ecd=bdc_podcast_libsyn_mscpedu
Join the program for an in-depth discussion on low-grade glioma – from burden and diagnosis to therapies.
Credit available for this activity expires: 12/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/pediatric-low-grade-glioma-braf-alterations-stories-science-2025a1000x3w?ecd=bdc_podcast_libsyn_mscpedu
Join this program for relevant updates across the advanced and metastatic breast cancer (mBC) spectrum as presented in October 2025.
Credit available for this activity expires: 12/8/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/hot-topics-berlin-2025-what-experts-say-about-future-2025a1000x8r?ecd=bdc_podcast_libsyn_mscpedu
Where do oral selective estrogen receptor degraders (SERDs) fit in the overall landscape of first- and second-line advanced/metastatic breast cancer?
Credit available for this activity expires: 12/04/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?ecd=bdc_podcast_libsyn_mscpedu
Preventing the first ASCVD is critically important. In this activity, we explore the evidence for early and intensive lipid lowering to significantly reduce patient's cardiovascular (CV) risk.
Credit available for this activity expires: 12/05/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/staying-ahead-first-event-evaluating-evidence-early-ldl-c-2025a1000xkj?ecd=bdc_podcast_libsyn_mscpedu
From the publisher's feed

1,262 Listeners

319 Listeners

496 Listeners

298 Listeners

1,388 Listeners

150 Listeners

892 Listeners

13 Listeners

16 Listeners

290 Listeners

3,343 Listeners

8,001 Listeners

195 Listeners

520 Listeners

372 Listeners

60 Listeners

26 Listeners

431 Listeners